AstraZeneca: new data supports heart drug Brilinta
(CercleFinance.com) - AstraZeneca's Brilinta monotherapy reduced the risk of bleeding compared to Brilinta plus aspirin in patients at high-bleeding risk who underwent cardiac procedure, new data showed.
Data from a Phase IV trial funded by AstraZeneca showed that in patients at high-bleeding risk who underwent percutaneous coronary intervention (PCI), Brilinta monotherapy was associated with a 44% lower risk of bleeding over one year.
In the trial, 9,006 patients received open-label Brilinta and aspirin for three months after a PCI.
The 7,119 patients that remained free of major bleeding or an ischemic event over the three months of treatment were randomized to either double-blinded aspirin or placebo for an additional 12 months, with continuation of Brilinta.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Data from a Phase IV trial funded by AstraZeneca showed that in patients at high-bleeding risk who underwent percutaneous coronary intervention (PCI), Brilinta monotherapy was associated with a 44% lower risk of bleeding over one year.
In the trial, 9,006 patients received open-label Brilinta and aspirin for three months after a PCI.
The 7,119 patients that remained free of major bleeding or an ischemic event over the three months of treatment were randomized to either double-blinded aspirin or placebo for an additional 12 months, with continuation of Brilinta.
Copyright (c) 2019 CercleFinance.com. All rights reserved.